Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on DBV Technologies (DBVT) to $48 from $42 and keeps an Overweight rating on the shares. DBV Technologies announced successful results from the Phase 3 VITESSE study of VIASKIN, with open-label extension enrollment trends in-line with previous studies and compliance “quite high” at over 96%, the analyst tells investors in a research note. Cantor is confident that these data check off the final box for a BLA submission in this patient population.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Optimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
- DBV Technologies price target raised to $51 from $35 at Guggenheim
- DBV Technologies price target raised to $45 from $21 at Citizens
- DBV Technologies trading resumes, shares up 65% to $29.60
- DBV Technologies jumps 79% after peanut allergy study hits endpoint